Federal Circuit Affirms PTAB Holding of No Interference in Fact in CRISPR Interference, Leaving Both Sides Free to License Their IP

Sep 14, 2018

Reading Time : 3 min

The CRISPR-Cas9 system is used to cut targeted DNA sequences, thereby allowing scientists to add, modify, or delete pieces of genetic material within an organism. Adapted from bacteria, the CRISPR-Cas9 system has been used to study mechanisms of disease and is currently being explored for possible applications in the treatment and prevention of various diseases in humans. It consists of three components, a crRNA molecule that targets a particular DNA sequence; a tracrRNA molecule that pairs with the crRNA molecule to form a functional guide RNA; and the Cas9 protein that interacts with the crRNA and tracrRNA and cuts DNA at the target location.

In 2012, researchers at the University of California, in collaboration with the University of Vienna and Emmanuelle Charpentier, demonstrated that the elements of the CRISPR-Cas9 system could be used in vitro. The following year, Broad Institute researchers published their results, showing the use of CRISPR-Cas9 in a human cell line. Both parties sought patent protection for their discoveries, and an interference was declared by the PTO. Notably, UC’s patent application claimed a method of cleaving nucleic acid using the CRISPR-Cas9 system, but did not specify the cell type or environment in which the system functioned. In contrast, Broad Institute sought claims that limited the use of the CRISPR-Cas9 system to eukaryotic cells. During the interference, Broad Institute argued that its claims were patentably distinct from UC’s claims because one skilled in the art would not have possessed a reasonable expectation that the CRISPR-Cas9 system would work in eukaryotic cells based on UC’s disclosures, including the 2012 article, which did not report any experimental results using eukaryotic cells.

The PTAB determines whether an interference exists by applying a two-way test in which it asks whether the claims of one party, if prior art, would have anticipated or rendered obvious the claims of the other or vice versa. Here, the PTAB agreed with Broad Institute and held that UC’s claims did not render Broad Institute’s claims obvious. More specifically, the PTAB held that, given the mixture of evidence in the record, including evidence of the difficulties associated with applying prokaryotic systems to eukaryotic cells, one skilled in the art would not have reasonably expected the CRISPR-Cas9 system to work in eukaryotes.

On appeal, UC argued that the PTAB adopted too rigid a test for obviousness when it looked for specific instructions in the prior art and erred in its treatment of evidence relating to simultaneous invention. The Federal Circuit disagreed with UC on both points. The Federal Circuit found the PTAB’s factual findings supported by substantial evidence, going so far as to say “[t]his case turns in its entirety on the substantial evidence standard.” 

Regarding UC’s first argument, the Federal Circuit noted the record contained evidence from witnesses for both parties that indicated the function of CRISPR-Cas9 in eukaryotes was unpredictable and could not be determined absent attempts to apply the system in eukaryotes. Evidence also demonstrated that similar prokaryotic systems could not be implemented in eukaryotes without tailoring the particular conditions of their use. In other words, a skilled artisan would not have reasonably expected the CRISPR-Cas9 system to work in eukaryotes based on the in vitro research performed by the UC scientists or based on related systems that had been disclosed in the art. And, although the prior art described mechanisms, i.e., provided general instructions, for implementing the CRISPR-Cas9 system in eukaryotes, the lack of specific instructions here combined with the prior failures supported the PTAB’s finding of no interference in fact.

The Federal Circuit similarly found no error in the PTAB’s evaluation of evidence relating to simultaneous invention. The court held the PTAB correctly recognized that simultaneous invention may be evidence of the level of skill in the art and objective evidence that persons of ordinary skill in the art recognized a problem and a solution to the problem. However, evidence of simultaneous invention, alone, cannot support an obviousness determination. More specifically, while simultaneous invention may show there is a motivation to combine prior art, it does not necessarily demonstrate an expectation of success. In this case, the balance of evidence, including the explicit statements of different inventors and the prior failures in the art, supported the PTAB’s determination that UC’s patent application did not render Broad Institute’s claims obvious.

Practice Tip:  Although this case is not particularly notable for its application of the law of obviousness, it provides a good example of a case in which the outcome on appeal was driven “in its entirety” by the standard of review. The Federal Circuit reviews the PTAB’s factual findings for substantial evidence. Thus, when appealing from the PTAB, it may be more important to identify gaps or discrepancies in the PTAB’s findings or identify a pure error of law than it is to assign errors to the PTAB’s application of facts to law.

Regents of the University of California v. Broad Institute, Inc., 2017-1907 (Fed. Cir. Sept. 10, 2018)

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.